Stuart Atkinson
Takeda Pharmaceutical Company
25 Papers
74 Citations
Stuart Atkinson is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Lansoprazole & Medicine. The author has an hindex of 10, co-authored 16 publications.
Chat about Author
Papers
Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease.
TL;DR: This study detected no difference in efficacy between lansoprazole and placebo for symptoms attributed to GERD in infants age 1 to 12 months.
363
Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.
TL;DR: In this article, the authors evaluated the relationship between intragastric pH and dexlansoprazole systemic exposure and delineate the exposure-response relationship following oral administration of dexlanoprazoles MR.
91
Helicobacter pylori-negative gastritis in erosive esophagitis, nonerosive reflux disease or functional dyspepsia patients.
TL;DR: The need for better characterization of gastric mucosal histology in these gastrointestinal disorders is highlighted, as chronic gastritis in H. pylori-negative subjects is more common than previously appreciated.
18
Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy.
Marian M. Haber,Barbara Hunt,James W. Freston,David A. Peura,Thomas O. Kovacs,Stuart Atkinson,M. Hisada +6 more
TL;DR: In this paper, the effect of long-term maintenance therapy with lansoprazole for erosive oesophagitis on gastric histology was evaluated in patients with EOG.
14
Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects.
TL;DR: In this study, dexlansoprazole MR administration results in moderate increases in PG, similar to lansopazole, which return to baseline levels within 7 days post dosing.
14